Literature DB >> 9333054

Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.

T L Wallace1, V Paetznick, P A Cossum, G Lopez-Berestein, J H Rex, E Anaissie.   

Abstract

The purpose of this study was to examine the activity of liposomal nystatin against a disseminated Aspergillus fumigatus infection in neutropenic mice. Mice were made neutropenic with 5-fluorouracil and were administered the antifungal drug intravenously for 5 consecutive days beginning 24 h following infection. Liposomal nystatin, at doses as low as 2 mg/kg of body weight/day, protected neutropenic mice against Aspergillus-induced death in a statistically significant manner at the 50-day time point compared to either the no-treatment, the saline, or the empty-liposome group. This protection was approximately the same as that for free nystatin, a positive control. Histopathological results showed that liposomal nystatin cleared the lungs, spleen, pancreas, kidney, and liver of Aspergillus and that there was no organ damage at the day 5 time point, which was after only three doses of liposomal nystatin. Based on these results in mice, it is probable that liposomal nystatin will be effective against Aspergillus infection in humans.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333054      PMCID: PMC164099     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  A case of aspergillosis treated with nystatin.

Authors:  L K MANNING; L ROBERTSON
Journal:  Br Med J       Date:  1959-02-07

Review 2.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 3.  Drug therapy reviews: clinical pharmacology and therapeutic use of antimycotic drugs.

Authors:  R H Meade
Journal:  Am J Hosp Pharm       Date:  1979-10

4.  Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria.

Authors:  R A Woods; M Bard; I E Jackson; D J Drutz
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

5.  Allergic pulmonary aspergillosis successfully treated with inhalations of nystatin. Report of a case.

Authors:  J E Stark
Journal:  Dis Chest       Date:  1967-01

6.  Nystatin (mycostatin) therapy in experimental coccidioidomycosis.

Authors:  L E GORDON; C E SMITH; D S WEDIN
Journal:  Am Rev Tuberc       Date:  1955-07

Review 7.  Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles.

Authors:  A H Thomas
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

8.  Amphotericin B-resistant yeast infection in severely immunocompromised patients.

Authors:  W G Powderly; G S Kobayashi; G P Herzig; G Medoff
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

9.  Nystatin (mycostatin) in the treatment of monilial and nonmonilial vaginitis.

Authors:  H R PACE; S I SCHANTZ
Journal:  J Am Med Assoc       Date:  1956-09-22

Review 10.  Overview of amphotericin B colloidal dispersion (amphocil).

Authors:  D A Stevens
Journal:  J Infect       Date:  1994-05       Impact factor: 6.072

View more
  18 in total

1.  New nystatin polymeric complexes and their in vitro antifungal evaluation in a model study with Fusarium oxysporum.

Authors:  Ekatherina Charvalos; Aristeidis Tsatsakis; Manolis Tzatzarakis; George Dolapsakis; John Stiakakis
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

2.  Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients.

Authors:  Y Krupova; M Mistrik; E Bojtarova; D Sejnova; I Ilavska; V Krcmery
Journal:  Support Care Cancer       Date:  2001-05       Impact factor: 3.603

3.  Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.

Authors:  Andreas H Groll; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Raul M Alfaro; Christine King; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 5.  [Anti-fungal drugs. Current status and guidelines for their administration].

Authors:  Rodrigo Fernández Alonso; Maria Esther González García; Joaquín Fernández García; Francisco Javier Cepeda Piorno
Journal:  Clin Transl Oncol       Date:  2005-10       Impact factor: 3.405

6.  Efficacy of 2-(3,4-dimethyl-2,5-dihydro-1h-pyrrole-2-yl)-1-methylethyl pentanoate in a murine model of invasive aspergillosis.

Authors:  Rajesh Dabur; S K Diwedi; V Yadav; V Mishra; Rambir Singh; H Singh; G L Sharma
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.

Authors:  A H Groll; V Petraitis; R Petraitiene; A Field-Ridley; M Calendario; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

8.  Nystatin induces secretion of interleukin (IL)-1beta, IL-8, and tumor necrosis factor alpha by a toll-like receptor-dependent mechanism.

Authors:  Raymund R Razonable; Martin Henault; Harold L Watson; Carlos V Paya
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

9.  Differential antifungal activity of isomeric forms of nystatin.

Authors:  L Ostrosky-Zeichner; S Bazemore; V L Paetznick; J R Rodriguez; E Chen; T Wallace; P Cossum; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

10.  Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations.

Authors:  E M Johnson; J O Ojwang; A Szekely; T L Wallace; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.